Cervomed announces presentation of biomarker data from the ascend-lb phase 2a trial and preclinical data supporting potential of neflamapimod in tau-mediated disease at ad/pd ™ 2024

- neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (gfap)

CRVO Ratings Summary

CRVO Quant Ranking